Home / Market News / $ACHV

$ACHV news and market catalysts

The 8 most recent market catalysts affecting $ACHV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 1 high impact 0 bullish 1 bearish Biotechnology
Nov 9, 2026 Corporate Catalyst Neutral Impact 55
Achieve Life Sciences Announces Rebranding to AchieveRx and Ticker Symbol Change
Achieve Life Sciences is rebranding to AchieveRx and changing its ticker to 'QUIT' in November 2026. This move is primarily a marketing and strategic alignment effort, aiming to be…
Oct 21, 2026 Corporate Catalyst Neutral Impact 65
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
Achieve Life Sciences (ACHV) presented 52-week clinical results for its cytisinicline candidate at the CHEST 2026 annual meeting. This filing indicates the company is providing lon…
Oct 21, 2026 Corporate Catalyst Neutral Impact 75
Achieve Life Sciences Presents 52-Week Cytisinicline Results From ORCA-OL Clinical Trial At CHEST 2026
The presentation of 52-week clinical trial results for Cytisinicline is a major corporate catalyst for Achieve Life Sciences. Positive data could significantly de-risk the drug's d…
Sep 30, 2026 Corporate Catalyst Neutral Impact 75
Stifel Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $18
Stifel's initiation of coverage on Achieve Life Sciences with a 'Buy' rating and an $18 price target is a significant positive catalyst for the company. Analyst coverage, especiall…
Sep 28, 2026 Corporate Catalyst Neutral Impact 75
Achieve Life Sciences To Present 52-Week Cytisinicline Data For Smoking And Vaping Cessation At CHEST 2026 On October 20
The presentation of 52-week data for Cytisinicline is a critical milestone for Achieve Life Sciences (ACHV). Positive results demonstrating efficacy and safety for smoking and vapi…
Aug 14, 2026 Corporate Catalyst Neutral Impact 65
Achieve Life Sciences Enters ATM Sale Agreement With Jefferies For Up To $150M In Common Stock
Achieve Life Sciences has established an At-The-Market (ATM) equity offering program, allowing it to sell up to $150 million of its common stock through Jefferies. This is a common…
Aug 13, 2026 Corporate Catalyst Neutral Impact 65
Morgan Stanley Initiates Coverage On Achieve Life Sciences with Overweight Rating, Announces Price Target of $13
Morgan Stanley analyst Maxwell Skor initiated coverage on Achieve Life Sciences (ACHV) with an Overweight rating and a $13 price target. This is a significant event for ACHV as new…
Aug 11, 2026 Corporate Catalyst Bearish Impact 95
Achieve Life Sciences Q2 EPS $(0.80) Misses $(0.16) Estimate
Achieve Life Sciences (ACHV) reported a Q2 EPS of $(0.80), which was a substantial miss compared to the analyst estimate of $(0.16). This 400% deviation from expectations, coupled …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.